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Abstract: This review describes the synovial response to treatment in peripheral spondyloarthritis (SpA). A series of 
recent studies demonstrates that the synovial histopathology is largely homogenous between different SpA subtypes and 
can be strongly modulated by effective treatment such as tumor necrosis factor (TNF) blockade. This includes a dramatic 
reduction of the infiltration with inflammatory cells (with the intriguing exception of B lymphocytes and plasma cells), a 
modulation of structural features such as vascularity, intimal lining layer hyperplasia, and ectopic lymphoid neogenesis, 
and a down-regulation of a variety of mediators involved in tissue damage. The analysis of tissue response to targeted 
therapies appears to be a novel and elegant approach to study the immunopathology of human peripheral SpA in vivo. 
Moreover, detailed cellular and molecular analysis of synovial features allows to identify synovial biomarkers of clinical 
response to therapeutic interventions which can be used in future early phase clinical trials in SpA. 
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INTRODUCTION 
  The successful introduction of tumor necrosis factor 
(TNF) blockade as a highly effective treatment for the 
different subtypes of spondyloarthritis (SpA) [1-4] has 
dramatically improved the clinical outcome and quality of 
life of SpA patients. An unforeseen consequence of this 
therapeutic success, however, is that clinical trial design in 
SpA is becoming increasingly challenging. On the one hand, 
the development of new treatment strategies is still necessary 
for the following reasons: 1) TNF blockade can be 
contraindicated in a subset of patients due to its safety 
profile, 2) a subset of treated patients experience an 
incomplete or non-response [5], 3) even in those patients 
with good clinical response, there is no convincing evidence 
yet that TNF blockade halts ankylosis [6, 7], 4) TNF 
blockade fails to induce a genuine sustained remission since 
almost all patients relapse shortly after treatment 
discontinuation [8]. 
  On the other hand, the dramatic clinical efficacy of TNF 
blockade in a majority of patients questions the medical and 
ethical acceptability of large, long-term placebo-controlled trials 
in SpA. Therefore, it becomes increasingly important for new 
candidate drugs to ‘fail fast’, meaning that early phase proof-of-
concept trials of limited size and treatment duration should lead 
to convincing ‘go/no go’ signals before proceeding with large 
long-term trials. Those drugs that fail in these proof-of-concept 
trials should not be used in larger patient populations, whereas 
obviously large scale phase IIb and III studies remain warranted 
to formally prove efficacy and safety for those drugs that make 
it through the proof-of-concept trials. 
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  One way to address this new challenge is to develop 
sensitive biomarkers of treatment response. A biomarker is a 
characteristic that can be objectively measured and evaluated 
as an indicator of a normal biologic process, a 
pathophysiologic process, or a pharmacologic response to 
therapeutic intervention [9]. As such, changes in biomarkers 
during treatment indicate that this treatment has a genuine 
effect on a specific biologic process of interest. When such a 
marker additionally reflects a clinical outcome in a reliable, 
sensitive, and reproducible way, it can be evaluated as 
surrogate marker in individual patients. In the context of 
early proof-of-concept evaluation of new treatment 
modalities, one aims to see a clear biological effect at the 
group level rather than to predict individual clinical 
responses. Accordingly, we will focus here on biomarkers in 
this specific context and will not discuss their potential 
application as surrogate markers in clinical practice. 
SYNOVIAL IMMUNOPATHOLOGY OF THE DIFFE-
RENT SpA SUBTYPES 
  SpA has traditionally been subdivided in specific subsets 
(AS, reactive arthritis or ReA, psoriatic arthritis or PsA, 
inflammatory bowel disease (IBD)-associated arthritis, and 
undifferentiated SpA or USpA) according to the phenotypic 
presentation. This phenotypic classification reflects the fact 
that SpA can affect different tissues (synovium, enthesis 
and/or bone) in both axial and peripheral joints and is 
frequently associated with extra-articular manifestations in 
the gut (IBD), the skin (psoriasis), and the eye (acute anterior 
uveitis). More recently, the ASAS group is working on a 
new classification in axial SpA and peripheral SpA based on 
the observation that early forms of SpA often do not display 
yet all clinical features required for the classical phenotypic 
subclassification. The prototypical example is early axial 
SpA characterized by inflammatory low back pain which, 
however, can not be classified as AS because the radiologic 
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duration. Whereas this novel classification is expected to 
solve, at least partially, the issue of early disease, the main 
challenge remains to determine whether the different SpA 
subtypes and in particular the axial versus peripheral 
manifestations are driven by the same pathophysiological 
processes. Data of a recent cross-sectional inception cohort 
indicate that approximately 40% of the SpA patients have 
pure axial disease, 20% have exclusively peripheral joint 
involvement, and 40% have a combined phenotype with both 
axial and peripheral joint involvement (Paramarta et al, 
manuscript in preparation). In the context of biomarker 
research, the phenotypic diversity of SpA raises a double 
question: which biological compartment should be analyzed 
and are the pathophysiologic processes under investigation 
in this compartment similar in the different SpA subtypes? 
  As to the first question, it is important to notice that SpA 
is not a genuine systemic disease but rather a disorder which 
specifically affects distinct tissues exposed to mechanical or 
microbial stress. Accordingly, it is more likely that important 
pathophysiologic processes can be detected in the affected 
tissue than in peripheral blood. Of the affected tissues, the 
axial skeleton is the most frequent site of inflammation in 
AS as well as SpA as a whole but is extremely difficult to 
access. The studies of inflamed axial tissue are thus 
restricted to surgical samples or necropsy material [10, 11] 
and sequential sampling during treatment is technically 
impossible. In contrast, peripheral joint synovium, gut tissue, 
and skin can easily be accessed during active disease. As no 
studies have been performed on sequential gut biopsies in 
SpA and as tissue response in the skin in the context of PsA 
will be discussed in a separate chapter of this journal, we 
will focus here on peripheral joint synovium. Indeed, this 
tissue is an attractive target for biomarker research since 
more than half of the SpA patients and approximately one 
third of the AS patients have peripheral disease with 
preferential involvement of large joints such as ankles and 
knees, from which it is relatively easy to obtain sequential 
synovial tissue biopsies by needle arthroscopy [12]. As the 
synovial immunopathology is unaltered by the procedure or 
by ineffective therapy [13, 14], this approach allows to 
investigate the modulation of synovial immunopathology by 
novel treatments. 
  The second question is whether the synovial 
immunopathology is similar or not between different SpA 
subtypes. A number of early studies have compared the 
synovial histopathology of distinct SpA subtypes with 
rheumatoid arthritis (RA) (Fig. 1). The most consistent 
finding of these studies is a decreased synovial lining 
hyperplasia and an increased vascularity in both ReA and 
PsA in comparison with RA [15-20]. However, none of these 
studies directly compared different SpA subtypes. A recent 
systematic comparison between AS/USpA, PsA, and RA 
showed that the SpA subtypes shared the same immuno-
pathologic features with significantly greater vascularity as 
well as infiltration with neutrophils and CD163+ 
macrophages compared to RA [21]. In contrast, lining layer 
thickness and the number of CD83+ dendritic cells were 
significantly increased in RA compared to AS/USpA as well 
as to PsA. In line with previous studies [22, 23], none of the 
SpA subtypes had positive staining for intracellular citrulli-
nated proteins or major histocompatibility complex/human 
cartilage glycoprotein-39 complexes whereas >40% of the 
RA samples were positive for both markers. Moreover, there 
were no histological differences between oligo-articular and 
poly-articular PsA. 
 The pathophysiologic similarities in synovial 
inflammation between different SpA subtypes and in 
particular between AS/USpA and PsA have recently been 
confirmed by the analysis of the inflammatory milieu in SpA 
and RA: the different SpA subtypes showed a consistent 
decrease in classically activated macrophage-derived 
mediators such as TNF and IL-1 in comparison with RA 
[24]. Coming back to the question which tissue should be 
sampled, it is also important to note that the alternatively 
activated CD163+ macrophages were not only increased in 
SpA synovium but also in gut biopsies of SpA and IBD 
patients [25, 26]. Although further research in potential 
synovial differences between SpA subtypes remains 
warranted, these data consistently indicate that the different 
SpA subtypes have largely similar synovial immunopatho-
logical characteristics which discriminates them from other 
inflammatory arthritides such as RA [27, 28]. 
MODULATION OF SYNOVIAL IMMUNOPATHO-
LOGY BY TNF BLOCKADE IN SpA 
  As there are no studies on synovial tissue response to 
treatment in AS solely but only in SpA as a group, and as the 
previously described synovial features correlate with disease 
activity across the different SpA subtypes [29], we will 
review the synovial response to treatment for the peripheral 
SpA group as a whole. Indeed, the only subset of SpA which 
has been studied as a separate entity is PsA as discussed in a 
different review article in this issue of the journal. Although 
in RA (and to a lesser extend in PsA) the synovial tissue 
response has been studied for a large array of disease 
modifying antirheumatic drugs (DMARDs) and biologicals 
[30-34], studies in SpA have only assessed the effect of TNF 
blockade with infliximab [14, 35] and etanercept [36]. This 
is partially related to the lack of efficacy of classical 
DMARDs, with the exception of sulphasalazine, as well as 
novel biologicals in peripheral SpA. It remains thus unclear 
whether the synovial changes observed with TNF blockers 
reflect specific mechanisms of action of this class of drugs or 
can be used more broadly as biomarkers of effective 
treatment in peripheral SpA. 
MODULATION OF THE INFLAMMATORY CELL 
INFILTRATION 
  A first major observation is that the global inflammatory 
cell infiltration is significantly reduced upon treatment with 
TNF blockade. Studies with infliximab in patients with 
different SpA subtypes demonstrated that especially 
infiltrating polymorphonuclear (PMN) cells and MRP8+ 
monocytes were rapidly reduced, which was already the case 
1 or 2 weeks after the first infusion [35]. This trend was 
further confirmed after 12 weeks of infliximab, when not 
only infiltrating monocytes and granulocytes, but also 
resident tissue CD163+ macrophages and T lymphocytes 
were significantly reduced [14, 35, 37]. Similar effects were 
observed with etanercept and the decrease in synovial 
infiltration was maintained or even augmented on the long 
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  The decrease of the cellular infiltration upon TNF 
blockade could be due to a diminished influx, an increased 
local apoptosis, and/or an accelerated efflux of these cells. 
The fact that the number of infiltrating MRP8+ and MRP14+ 
monocytes is reduced more rapidly and more profoundly 
than the number of CD163+ resident tissue macrophages in 
the synovial tissue, together with the early and significant 
decrease of serum MRP8/MRP14 levels in contrast to the 
sCD163 levels, strongly suggest a primary effect on 
inflammatory cell recruitment into the inflamed synovial 
tissue by TNF blockade [37]. This hypothesis is further 
confirmed by the treatment-induced down-regulation of the 
number of synovial blood vessels as assessed by CD146 and 
von Willebrand Factor (vWF) immunostaining as well as the 
expression of markers of neovascularisation such as V3 
integrin, angiogenic factors such as synovial matrix 
metalloproteinase (MMP)-9, and adhesion molecules [14, 
35, 36, 38, 39]. The reduction of hypervascularity and 
endothelial activation is likely to restrain the migration and 
homing of inflammatory cells into the synovium. 
  As for the contribution of local cell death, a couple of 
studies in Crohn’s disease have proposed that apoptosis of 
activated lymphocytes by outside-in signaling is likely to   
 
play a role in the immunomodulating effect of infliximab. 
The absence of this effect by etanercept could thus 
potentially explain the lack of efficacy of this drug in IBD. 
However, the successful use of certolizumab, a pegylated 
TNF blocker which does not induce cell death, in Crohn’s 
disease [40, 41] challenges this theory. As to arthritis, only 
one study in RA has reported a contribution of apoptosis to 
the synovial effects of TNF blockade [42]. In contrast with 
the IBD studies, this report suggests apoptosis of 
macrophages rather than lymphocytes and found this effect 
both with etanercept and infliximab. However, the large 
majority of studies in RA, PsA, as well as SpA could not 
provide evidence for an increased synovial cell death upon 
TNF blockade, making it unlikely that this mechanism plays 
a dominant role in the synovial tissue response [43-46]. 
  A third and most intriguing hypothesis is that TNF 
blockade does not only reduce the influx but also promotes 
the efflux of inflammatory cells from the inflamed tissue. 
This theory is supported by a recent study in the TNF 
transgenic mouse model of arthritis showing an increase of 
synovial lymphatic vessels upon TNF blockade [47]. A 
similar increase of lymphatic vessels was observed in RA 
and SpA synovium upon infliximab treatment. 
 
 
Fig. (1). Distinct features of SpA synovitis. In comparison with RA, SpA synovitis displays less synovial lining layer hyperplasia (A), the 
abcens of intracellular citrullinated proteins (B), and the absence of HLA-DR4/HC gp-39 peptide complexes (C). Vascularity (D) as well as 
infiltration with polymorphonuclear cells (E) and CD163+ macrophages (F) is clearly increased in SpA. Depositions of uridic acid crystals 
(G), homogentisic acid (H), and hemosiderin (I) are typical for gout, ochronosis, and pigmented villonodular synovitis, respectively, and are 
not found in SpA synovitis. 130   The Open Rheumatology Journal, 2011, Volume 5  Paramarta et al. 
MODULATION OF SYNOVIAL B LYMPHOCYTES 
  In sharp contrast with the effect on neutrophils, 
macrophages, and T lymphocytes, the synovial infiltration 
with B cells and plasma cells was not reduced upon 
treatment and in a few cases the presence of plasma cells was 
even clearly augmented [14, 35-37]. Downregulation of the 
number of CD68+ macrophages and T cells with unchanged 
number of B cells and plasma cells was also observed in two 
other studies involving treatment with infliximab in patients 
with PsA [45, 48]. Whereas the exact biological meaning 
and the underlying mechanisms of these findings are still 
unclear, it suggests that TNF blockade does not affect or 
even promotes infiltration, survival, local proliferation, 
and/or differentiation of B cells but no other leucocytes. 
Interestingly, this phenomenon is completely uncoupled 
from clinical or histological inflammation and thus indicates 
that these B cells and plasma cells are probably not primary 
players in the synovial immunopathology in SpA [49]. This 
should also be interpreted in the context of other signs of de 
novo B cell activation upon treatment with infliximab such 
as the impressive induction of anti-nuclear antibodies (ANA) 
and IgM anti-dsDNA antibodies [50, 51] and warrants 
further investigation of B cell biology in SpA. 
  In this context, it is interesting to note that the 
microarchitectural organization of infiltrating B cells in 
ectopic lymphoid structures is not restricted to seropositive 
diseases such as RA but is equally found in seronegative 
joint inflammation including the different subtypes of SpA 
[52-55]. Accordingly, synovial ectopic lymphoid neogenesis 
is more related to the degree of local inflammation than to 
the presence of autoantibodies and is downregulated by TNF 
blockade in SpA. 
MODULATION OF TLR EXPRESSION 
  It has been suggested that activation of innate immune 
cells in the gut and in the joints by microbial pathogens may 
be relevant to inflammation in SpA with a special role for 
the CD163+ macrophage subpopulation [25]. This has been 
linked to toll like receptors (TLRs). TLR-2 and TLR-4 bind 
to components of both Gram-positive and Gram-negative 
bacteria. Following ligand binding TLRs activate a signaling 
cascade which results in the production of mediators of 
inflammation. TLRs have been identified in RA synovium 
and have been shown to play an important functional role in 
experimental arthritis models. The synovial expression of 
both TLR-2 and TLR-4 is significantly higher in SpA than in 
RA despite similar levels of local inflammation [56]. Both 
infliximab and etanercept sharply down-regulate the synovial 
TLR expression. These findings highlight the potential role 
of innate immunity related inflammation in SpA and provide 
new insights into the mode of action of TNF blockade. 
MODULATION OF STRUCTURAL DAMAGE 
  As the inflamed synovium plays a crucial role in 
structural damage to articular cartilage and bone, it is 
important to know whether TNF blockade only blocks 
inflammation or also affects mechanisms of joint destruction. 
The synovial intimal lining layer, consisting of both 
fibroblast-like synoviocytes (FLS) and macrophages, plays 
an important role in this process by promoting osteoclast 
differentiation and activation through the RANK-RANKL 
system, by production of MMPs which can degrade 
cartilage, and by a direct effect of the FLS-adhesion 
molecule cadherin-11 on cartilage [57]. 
  TNF blockade appears to influence several of these 
factors in the inflamed SpA synovium. Firstly, TNF 
blockade reduces the degree of lining layer hyperplasia [14, 
35, 36]. The thickness of the synovial lining was even 
normalized after long-term treatment. This effect is likely to 
be mediated by a reduction of TNF-induced proliferation 
and/or a restoration of Fas-mediated apoptotic cell death of 
synovial fibroblasts [58], since the number of CD55+ 
synovial lining fibroblasts were significantly reduced after 
treatment [35]. Secondly, both MMPs and their inhibitors, 
tissue inhibitor metalloproteinases (TIMPs), were not only 
abundantly expressed in SpA synovitis but were rapidly and 
profoundly downregulated by TNF blockade [39]. Thirdly, 
the expression of cadherin-11 by FLS appeared to be TNF-
driven  in vitro and, accordingly, was significantly 
downregulated by anti-TNF treatment in vivo [59]. All these 
effects may contribute to halt the structural damage as 
demonstrated by the absence of progression of radiological 
damage over a 2-years period of follow up [36]. 
  In contrast with MMPs and cadherin-11, the abundant 
synovial expression of RANK, RANKL, and osteoprotegerin 
(OPG) in SpA synovitis appeared to be largely independent 
of the degree of synovial inflammation and was thus only 
downregulated by TNF blockade in the subset of patients 
with the largest systemic response [60]. However, this 
absence of effect on the RANK/RANKL/OPG system does 
not necessarily mean that TNF blockade does not affect 
osteoclast differentiation and activation as TNF itself has a 
direct role in this process [61]. Finally, it should be noted 
that the effect of TNF blockade on synovial mediators of 
new bone formation and ankylosis, such as the bone 
morphogenetic protein (BMP) and Wnt signaling pathways, 
remains largely unexplored in SpA. 
CONCLUSIONS AND FUTURE DIRECTIONS 
  Taken together, these studies demonstrate that the 
synovial histopathology is largely homogenous between 
different peripheral SpA subtypes and can be strongly 
modulated by effective treatment such as TNF blockade. 
This includes a dramatic reduction of the infiltration with 
inflammatory cells (with the intriguing exception of B 
lymphocytes and plasma cells), a modulation of structural 
features such as vascularity, lining layer hyperplasia, and 
ectopic lymphoid neogenesis, and a down-regulation of a 
variety of mediators involved in tissue damage. 
  The analysis of tissue response to targeted therapies 
appears to be a novel and elegant approach to study the 
immunopathology of human disease in vivo. This is of 
particular importance in SpA as there is scarcity of 
appropriate experimental models for this disease. The use of 
such therapies allows to assess if such pathways are TNF-
driven or not and whether specific cell types or molecules 
really contribute to the synovial inflammation. Although the 
studies performed until today are largely restricted to 
immunohistology, the translational combination of novel 
targeted therapies and more sophisticated molecular methods 
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receptor (BCR) repertoires, … are likely to reveal 
fundamental disease mechanisms in the near future [62-64]. 
  The discussed studies also raise the possibility to use 
synovial immunopathology as an additional biomarker to 
discriminate between effective and ineffective treatment in 
early phase clinical trials in SpA. In a proof-of-concept 
study, we demonstrated that changes in different macrophage 
subsets (CD163+ resident tissue macrophages and 
infiltrating MRP8+ or MRP14+ monocytes), PMN cells, and 
MMP-3 expression are superior to C reactive protein (CRP) 
to discriminate between TNF blockade and placebo 
treatment in SpA [65]. As not all SpA patients have 
peripheral arthritis and as it remains unclear to what extend 
peripheral and axial disease are driven by the same 
processes, it is important that several synovial markers (such 
as MMP-3 and MRP8/14) can easily and reliably be 
measured in serum [37, 39, 66]. This approach will not be 
restricted to markers of synovial inflammation as soluble 
biomarkers of cartilage and bone metabolism also appears to 
be modulated by TNF blockade in SpA [67, 68]. The main 
challenge will thus be to set up a panel of reliable markers 
reflecting the pivotal biologic processes of SpA pathogenesis 
(including enchondral bone formation) and to assess this 
panel across different targeted treatment strategies in both 
axial and peripheral SpA. 
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